InflaRx N.V. (IFRX)

NASDAQ: IFRX · Real-Time Price · USD
1.150
-0.100 (-8.00%)
At close: Mar 28, 2025, 4:00 PM
1.215
+0.065 (5.61%)
After-hours: Mar 28, 2025, 5:30 PM EDT
-8.00%
Market Cap 77.74M
Revenue (ttm) 171,642
Net Income (ttm) -47.69M
Shares Out 67.60M
EPS (ttm) -0.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 346,081
Open 1.230
Previous Close 1.250
Day's Range 1.140 - 1.280
52-Week Range 1.132 - 2.815
Beta 1.99
Analysts Strong Buy
Price Target 9.00 (+682.61%)
Earnings Date Mar 20, 2025

About IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflamma... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2017
Employees 74
Stock Exchange NASDAQ
Ticker Symbol IFRX
Full Company Profile

Financial Performance

In 2024, InflaRx's revenue was 165,789, an increase of 162.79% compared to the previous year's 63,089. Losses were -46.06 million, 7.96% more than in 2023.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for IFRX stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 682.61% from the latest price.

Price Target
$9.0
(682.61% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...

10 days ago - GlobeNewsWire

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced th...

23 days ago - GlobeNewsWire

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acc...

4 weeks ago - GlobeNewsWire

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...

4 weeks ago - GlobeNewsWire

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, ann...

5 weeks ago - GlobeNewsWire

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, ann...

6 weeks ago - GlobeNewsWire

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, ann...

6 weeks ago - GlobeNewsWire

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...

2 months ago - GlobeNewsWire

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced tha...

2 months ago - GlobeNewsWire

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced tha...

3 months ago - GlobeNewsWire

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced tha...

4 months ago - GlobeNewsWire

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

JENA, Germany, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced fin...

5 months ago - GlobeNewsWire

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced th...

6 months ago - GlobeNewsWire

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced th...

7 months ago - GlobeNewsWire

InflaRx Announces Participation in September Investor Events

JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...

7 months ago - GlobeNewsWire

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

JENA, Germany, Aug. 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced fin...

8 months ago - GlobeNewsWire

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...

8 months ago - GlobeNewsWire

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today ...

9 months ago - GlobeNewsWire

InflaRx Hosts R&D Event Highlighting the Promise of INF904

JENA, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a v...

10 months ago - GlobeNewsWire

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data pr...

11 months ago - GlobeNewsWire

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

JENA, Germany, May 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced fina...

11 months ago - GlobeNewsWire

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced tha...

1 year ago - GlobeNewsWire

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

JENA, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its...

1 year ago - GlobeNewsWire

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...

1 year ago - GlobeNewsWire

InflaRx Appoints Jan Medina as Head of Investor Relations

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...

1 year ago - GlobeNewsWire